6 Results Found

Advanced Search

Select all

Results per page

Select all

Article

1 Citations

2,046 Views

11 Pages

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma

Fabrizio Huwyler,
Rebekka Kunz,
Ulrike Bacher,
Michèle Hoffmann,
Urban Novak,
Michael Daskalakis,
Yara Banz and
Thomas Pabst

Cancers2023, 15(7), 2091;https://doi.org/10.3390/cancers15072091

31 March 2023

(1) Background: First-line therapy in fit MCL patients may comprise high-dose chemotherapy (HDCT) with autologous transplantation to consolidate remission before maintenance treatment. However, optimization of HDCT is an unmet clinical need given the...

Full Article

Article

1 Citations

2,154 Views

12 Pages

BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia

Alexander D. Heini,
Philipp Beck,
Ulrike Bacher,
Katja Seipel,
Thilo Zander,
Michael Daskalakis and
Thomas Pabst

J. Clin. Med.2023, 12(6), 2378;https://doi.org/10.3390/jcm12062378

19 March 2023

High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is an option to consolidate remission in Waldenstrom’s macroglobulinemia (WM), particularly in selected younger patients with chemosensitive disease. BEAM, consistin...

Full Article

Article

5 Citations

2,877 Views

10 Pages

BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL—A Pilot Study

Tanja Stoffel,
Ulrike Bacher,
Yara Banz,
Michael Daskalakis,
Urban Novak and
Thomas Pabst

J. Clin. Med.2022, 11(13), 3748;https://doi.org/10.3390/jcm11133748

28 June 2022

(1) Introduction: BEAM is a high-dose chemotherapy (HDCT) frequently administered before autologous stem cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Bendamustine replacing BCNU (BeEAM) is similarly effective at lower toxicit...

Full Article

Article

3 Citations

2,247 Views

12 Pages

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study

Christian Rausch,
Ulrike Bacher,
Manuela Rabaglio,
Corinne Vorburger,
Anke Klingenberg,
Yara Banz,
Michael Daskalakis and
Thomas Pabst

J. Clin. Med.2022, 11(18), 5378;https://doi.org/10.3390/jcm11185378

13 September 2022

The prognosis for patients with CD30+ lymphomas (Hodgkin lymphoma and various T-cell lymphomas) relapsing after autologous stem cell transplantation (ASCT) is critical. Brentuximab vedotin (BV), an ADC targeting CD30, is an obvious candidate for incl...

Full Article

Article

1 Citations

2,241 Views

18 Pages

Verification of a Modeling Toolkit for the Design of Building Electrical Distribution Systems

Anay Waghale,
Shat Pratoomratana,
Tianna-Kaye Woodstock,
Karthikeya Devaprasad and
Michael Poplawski

Buildings2023, 13(10), 2520;https://doi.org/10.3390/buildings13102520

5 October 2023

DC electrical distribution systems offer many potential advantages over their AC counterparts. They can facilitate easier integration with distributed energy resources, improve system energy efficiency by eliminating AC/DC converters at end-use devic...

Full Article

Article

5 Citations

2,271 Views

46 Pages

A Modeling Toolkit for Comparing AC and DC Electrical Distribution Efficiency in Buildings

Avpreet Othee,
James Cale,
Arthur Santos,
Stephen Frank,
Daniel Zimmerle,
Omkar Ghatpande,
Gerald Duggan and
Daniel Gerber

Energies2023, 16(7), 3001;https://doi.org/10.3390/en16073001

25 March 2023

Recently, there has been considerable research interest in the potential for DC distribution systems in buildings instead of the traditional AC distribution systems. Due to the need for performing power conversions between DC and AC electricity, DC d...

Full Article